| Experiment ID | EXP00105 |
| Reference | Title: Integrative genomic profiling of human prostate cancer. Author: Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK,Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, MajorJE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE,Scardino PT, Sander C, Sawyers CL, Gerald WL. Journal: Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010Jun 24. Abstract: Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copynumber, mRNA expression, and focused exon resequencing in 218 prostate cancertumors identified the nuclear receptor coactivator NCOA2 as an oncogene inapproximately 11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusionwas associated with a previously unrecognized, prostate-specific deletion atchromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperativetumor suppressors. DNA copy-number data from primary tumors revealed thatcopy-number alterations robustly define clusters of low- and high-risk diseasebeyond that achieved by Gleason score. The genomic and clinical outcome data fromthese patients are now made available as a public resource. PMID: 20579941 |
| Expressiion Profile | Description: MicroRNA expression data for human primary and metastatic prostate cancer samples and control normal adjacent benign prostate Organism: Homo sapiens GEO ID: GSE21036 Platform: GPL8227 Number of samples: 142 |
| Design and Sample | Cancer Type: prostate cancer Cancer SubType: N/D Cell Line: N/D Experimental Design: high grade vs low grade Case Sample: prostate cancer gleason sum 8 Control Sample: prostate cancer gleason sum 7 Num of Case: 8 Num of Control: 39 Quantification Software: Limma Num of miRNAs: 373 |
| Identification | Num of Up: 2 Num of Down: 0 |